These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11593908)

  • 1. [Low dose brachytherapy with seeds--an interdisciplinary therapy alternative to radical prostatectomy].
    Kahmann F; Henkel T
    Praxis (Bern 1994); 2001 Sep; 90(36):1523-31. PubMed ID: 11593908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
    J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
    Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
    BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
    Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
    Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States.
    Lee WR; Moughan J; Owen JB; Zelefsky MJ
    Cancer; 2003 Nov; 98(9):1987-94. PubMed ID: 14584083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interstitial iodine 125 therapy in localized prostatic carcinoma. Results at the Utrecht University].
    Battermann JJ
    Praxis (Bern 1994); 2001 Sep; 90(36):1501-5. PubMed ID: 11593905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer.
    Langley SE; Laing RW
    Prostate Cancer Prostatic Dis; 2004; 7(3):201-7. PubMed ID: 15184864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advancement of treatment for prostate cancer].
    Hara I
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):178-82. PubMed ID: 16484852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.
    Sharkey J; Cantor A; Solc Z; Huff W; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R
    Brachytherapy; 2005; 4(1):34-44. PubMed ID: 15737905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate brachytherapy: a descriptive analysis from CaPSURE.
    Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
    Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma.
    Copeland LA; Elshaikh MA; Jackson J; Penner LA; Underwood W
    Cancer; 2005 Oct; 104(7):1372-80. PubMed ID: 16118801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.